The deal is Everstone’s third in the healthcare and wellness sector in less than a year. OmniActive said the funds would help it expand its portfolio beyond its core extracts range encompassing capsicain, curcumin, ginger, lutein, zeaxanthin and salacia – although it did not specify how exactly.
“This investment aims at helping OmniActive scale its already strong presence in the fast-growing nutraceutical space. We are excited about partnering with the Mariwala family and building a world class global business,” said Sameer Sain, co-founder and managing partner of Everstone Group, an India and Southeast Asia focused private equity and real estate investment firm with assets under management of US $3.3 billion
Sanjaya Mariwala, managing director of OmniActive Health Technologies, said: “We welcome this partnership with the Everstone Group. With the support of its experienced teams and funding, OmniActive looks forward to building on our history of solid organic growth by further strengthening our presence globally using innovative products and technologies.
“This will be done by also growing inorganically to bring a wider product portfolio of responsibly made ingredients to our customers through our strategic acquisitions.”.
Avendus Capital was advising OmniActive on this deal as the investment banker.
Mariwala told our sister site NutraIngredients-Asia: "With the entry of Everstone, we expect to see an acceleration of our inorganic growth strategy with acquisition of products, technologies and markets to complement our current targeted portfolio, including weight management, sports and performance nutrition, metabolic health and eye, brain and gut/digestive health."